Related Experiment Video
Updated: Jul 20, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
CT-Based Radiogenomics of P4HA3 Expression in Clear Cell Renal Cell Carcinoma
Federico Greco1, Andrea Panunzio2, Alessandro Tafuri2
1Department of Radiology, Cittadella della Salute Azienda Sanitaria Locale di Lecce, Piazza Filippo Bottazzi, 2, 73100 Lecce, Italy (F.G.).
Rationale And Objectives:
The sequencing of the renal cell carcinoma (RCC) genome identified several mutations with prognostic significance. Genomic analysis, collected in The Cancer Genome Atlas Research Network, revealed several clear cell renal cell carcinoma (ccRCC) gene mutations and gene expressions. Radiogenomics is a new branch of diagnostic imaging based on the association between imaging phenotypes and genomics of diseases. P4HA3 expression has recently been shown to correlate with increased aggressiveness of ccRCC, with poor prognosis, proliferation, migration, invasion, and metastases, suggesting P4HA3 as a prognostic marker and therapeutic target in ccRCC. The aim of this study is to investigate the computed tomography (CT) imaging phenotype of P4HA3 expression in ccRCC patients.
Materials And Methods:
In this retrospective study we enrolled 196 ccRCC patients divided into two groups: ccRCC patients with P4HA3 expression (n = 13) and ccRCC patients without P4HA3 expression (n = 183). Several imaging features were evaluated on preoperative CT scan. The statistical significance threshold was set at P < .05.
Results:
A statistically significant association was found with larger primary tumor size (P = .033), tumor infiltration (P = .023), ill-defined tumor margins (P = .025), and advanced tumor stage American Joint Committee of Cancer (P = .014).
Conclusion:
This study demonstrates CT imaging features associated with P4HA3 expression in ccRCC. These results could contribute to better understand P4HA3 expression with a noninvasive approach and could be applied to the development of targeted therapies.
Insights
Computed tomography (CT) imaging can identify P4HA3 expression in clear cell renal cell carcinoma (ccRCC). Larger tumors, infiltration, ill-defined margins, and advanced stage are linked to P4HA3 expression in ccRCC patients.
Area of Science:
- Oncology
- Radiology
- Genomics
Background:
- Renal cell carcinoma (RCC) genome sequencing reveals mutations with prognostic significance.
- P4HA3 expression correlates with ccRCC aggressiveness, poor prognosis, and metastasis, indicating its potential as a prognostic marker and therapeutic target.
- Radiogenomics explores the link between imaging phenotypes and disease genomics.
Purpose of the Study:
- To investigate the computed tomography (CT) imaging phenotype associated with P4HA3 expression in clear cell renal cell carcinoma (ccRCC).
- To establish a noninvasive method for assessing P4HA3 expression in ccRCC patients.
Main Methods:
- Retrospective study of 196 ccRCC patients, divided into P4HA3-expressing (n=13) and non-expressing (n=183) groups.
- Evaluation of various imaging features on preoperative CT scans.
- Statistical significance set at P < 0.05.
Main Results:
- Statistically significant associations found between P4HA3 expression and larger primary tumor size (P=0.033).
- P4HA3 expression was associated with increased tumor infiltration (P=0.023) and ill-defined tumor margins (P=0.025).
- A correlation was observed with advanced tumor stage (American Joint Committee of Cancer staging, P=0.014).
Conclusions:
- CT imaging features are associated with P4HA3 expression in ccRCC.
- These findings may aid in understanding P4HA3 expression noninvasively.
- The results could inform the development of targeted therapies for ccRCC.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018